MiNA Therapeutics is a pioneer in RNA activation therapeutics which is applied to treating cancer or rare genetic disorders.
Location: United Kingdom, England, London
Total raised: $44.46M
Investors 2
| Date | Name | Website |
| - | Bootstrap ... | bootstrap-... |
| 20.01.2022 | aMoon Fund | amoon.fund... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.07.2021 | - | $15M | - |
| 10.09.2020 | Series A | $29.46M | - |
Mentions in press and media 6
| Date | Title | Description |
| 01.09.2021 | The U.K. Genomics Startups Changing The Future Of Healthcare Forever | Genomics: the future of healthcare getty |
| 12.07.2021 | MiNA Therapeutics Receives $15M Equity Investment from Eli Lilly and Company | MiNA Therapeutics Limited, a London, UK-based provider of small activating RNA therapeutics, received a $15m equity investment from Eli Lilly and Company. The company intends to use the funds to advance and expand its internal pipeline of s... |
| 10.09.2020 | MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics | - |
| 10.09.2020 | MiNA raises $30M to take small activating RNA into phase 2 | MiNA Therapeutics has raised £23 million ($30 million) to advance a pipeline of small activating RNAs (saRNAs) aimed at previously undruggable targets. The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver can... |
| 10.09.2020 | MiNA Therapeutics Secures £23M Series A Financing | MiNA Therapeutics, a London, UK-based maker of RNA activation therapeutics, completed a £23m ($30m) Series A equity financing. The round was led by aMoon, with participation from existing investors. As part of the Series A financing, Dr. Gu... |
| 10.09.2020 | MiNA raises $30M to take small activating RNA into phase 2 | MiNA Therapeutics has raised £23 million ($30 million) to advance a pipeline of small activating RNAs (saRNAs) aimed at previously undruggable targets. The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver can... |